Wuhan General Group (China), Inc. (OTCPK: WUHN)
Health Care · Pharmaceuticals · US
$0.00
— today · +200.0% 1Y
Wuhan General Group (China), Inc. (OTCPK: WUHN) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $16.55K and employs 700 people.
Over the last twelve months the share price has gained 200.0%, trading between 0.00 and 0.00.
Tweenvest scores Wuhan General Group (China), Inc. across four factors: quality 43/100, value 44/100. Its strongest factor is value.
WUHN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $16.55K
- Revenue (TTM)
- $80.38M
- P/E
- —
- EPS
- -0.35
- Dividend yield
- —
- Beta (5Y)
- -1.21
- 52-week high
- $0.00
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 55.15M
- Employees
- 700
- Next earnings
- —
About Wuhan General Group (China), Inc.
Wuhan General Group (China), Inc. is a nutraceutical biotechnology company, which engages in the development of alternative plant-based cannabinoids and psilocybin medical research that commercializes a range of cannabidiol and mushrooms-based products under the Dr. AnnaRx, Medspresso and Handcrafted Delights brands. The firm is also engages in research and development of indications for psilocybin new therapies that will help patients who suffer from mental illness, Alzheimer's and Parkinson's. The company was founded by Xu Jie and Jeff Robinson on July 19, 1988 and is headquartered in Cape Town, South Africa.
- ISIN
- US9825691051
- Listed since
- Apr 19, 2006
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,256.19 | +0.06% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $271.00 | +0.28% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $153.00 | +0.29% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.30 | -1.41% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.00 | -1.14% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.13 | +0.21% |
Figures last refreshed Aug 18, 2026.